Daily Archives: May 22, 2019

Gainsight Launches Pulse+, The Online Media Platform for Customer Success Professional Development

Premium Offering Includes Industry Training and Certifications, Original Video Series, Exclusive Content and More

SAN FRANCISCO, May 22, 2019 (GLOBE NEWSWIRE) — Gainsight®, the customer success company, announced today Pulse+, a digital subscription service for professional development, community, and career fellowship in the customer success industry. The subscription-based online media platform will combine premium eLearning and industry-grade certifications with exclusive content and behind-the-scenes stories of brands and thought leaders who exemplify the true spirit of customer success. Subscribers will have unlimited and exclusive access to a continuously-updated, year-round program of on-demand training, original video series, podcasts, and more. Pulse+ aims to develop and advance the careers of skilled and aspiring customer success professionals around the world.

In 2015, Gainsight created Customer Success University to help customer success professionals learn and apply new skills to their business through courses, certifications, and training. Since then, it has evolved as Pulse Academy to become the leading customer success training program, educating over 8,000 people globally. At the same time, the role of Customer Success Manager has seen a 736 percent increase since 2015 and is now one of the top 10 fastest growing professions according to LinkedIn. As a result, Gainsight launched Pulse+ to support and develop the careers of customer success professionals at scale and across the globe – a necessary step to keep up with the growth of the profession.

“We realized that it’s important to foster a community of diverse perspectives and cutting-edge lessons from industry leaders and experienced practitioners who work every day on driving success for their customers,” said Ruben Rabago, Chief Strategist of Pulse Customer Success Programs. “Pulse+ allows us to encapsulate this special-sauce into a learning experience that’s on-demand and delivered at scale, bringing highly curated content and certification learning paths into the daily flow of work. This initiative is a purposeful commitment by Gainsight to continue to advance the customer success profession worldwide.”

Pulse+ will offer courses in a broad range of customer success topics and areas of expertise, with new content added monthly. Initial courses will cover subjects including The Importance of Nailing the Handoffs, Product Must Be The Top Priority, and What to Present to your Board of Directors about CS. New courses will feature exclusive video series, supplemental materials, ask-me-anything sessions, peer discussions, and other related content to support meaningful educational experiences. The collection of content is designed to enable professionals with impactful learning through a curated selection of the top technical and business skills in the customer success industry.

Subscribers will also have access to:

  • Customer success training and certification: Subscribers can engage with customer success courses curated by subject matter experts and thought leaders, and then earn the most authoritative customer success certification in the industry.
  • Premium, expert-level content on industry best practices
  • New content every month for every skill level
  • Preferred VIP and discounted ticket prices for Pulse events worldwide.

“I would highly recommend that anyone interested to learn or grow their knowledge of CS consider investing in the GS Pulse+ program – they won’t be disappointed.” – Bryan W. Hochstein, Ph.D., Assistant Professor Of Marketing

“Although I’ve been a client success leader for several years, Pulse+ helped me create a consistent framework of industry best practices and terminology, and sparked new ideas that helped us move the needle as a team.” – Shar Jordan, VP Of Client Experience, IBM

Pulse Academy (included with Pulse+) is the most impactful investment we’ve ever made in our customer success team — and, ultimately in our customers — period. From “ah-ha” moments to take-home insights, we left with priceless lessons and materials that will guide our commitment to being a customer-centric business from the top-down.” Paul M. Bernard, President and Chief Executive Officer, CallMiner

The annual subscription is priced at $75/month. To celebrate the release of Pulse+ at Pulse 2019, anyone signing up before May 31, 2019, will receive a 50% discount to the first year of their subscription. Pulse+ is powered by eLearning partners Intellum, Allen Interactions, and EdgePoint Learning.

About Gainsight: Gainsight® is the leading SaaS solution helping companies retain customers and grow revenue by improving their customer success and product experience. The platform provides relevant customer information and predictive analytics and turns them into actionable insights that anticipate customer needs. Learn how leading companies like Adobe, Box, GE Digital and Workday use Gainsight to increase retention, expansion, and advocacy at www.gainsight.com.

Contact: press@gainsight.com

LGC Capital announces that it has increased its ownership to 40.4% of Little Green Pharma in Australia

MONTRÉAL, May 22, 2019 (GLOBE NEWSWIRE) — LGC Capital Ltd. (TSXV: LG) (OTCQB: LGGCF) (“LGC” or the “Corporation”) announces that after much negotiation, it has successfully acquired, from a non-executive founder, additional shares in Australia’s licensed medical cannabis producer Little Green Pharma (LGP) bringing its ownership from 14.1% up to 40.4%.

LGP was the first, and is currently the only, domestic cannabis company in Australia producing a locally grown medicinal cannabis medicine for patients.  LGC believes the opportunity to increase its ownership in LGP creates significant value for its shareholders and enables the Corporation to further take part in the rapidly expanding Australian medical cannabis market.

Little Green Pharma has had over 400 patients approved in Australia, with new patients increasing exponentially month-over-month. The Australian industry represents one of the fastest growing international medical cannabis markets globally, with approximately 6,400 SAS B forms approved to the end of April 2019 of which 1,110 occurred in April alone.  Prohibition Partners estimates that the Australian medical cannabis market could be worth US$2 billion by 2028 and US$8.7 billion if adult use was to become legal.

Little Green Pharma produces its products in compliance with Australia’s strict Therapeutic Goods Order 93 Standard for Medicinal Cannabis and is one of only a handful of companies with an EU GMP recognised medical cannabis facility.

Expansion plans for LGP‘s cultivation facility have been submitted to Australia’s Office of Drug Control to increase production capacity in order to supply the Company’s growing demand for its products in Australia as well as to export product via its new distribution agreements in Germany, the United Kingdom, Canada and New Zealand.

Mazen Haddad, CEO of LGC Capital, stated; “Little Green Pharma was one of our first investments and as its business and opportunities expanded, and the opportunity to increase our shareholding to over 40% is a significant move for the Company. To be the first in Australia to grow and produce a full line of Medical THC Cannabis products, in accordance with both Australian and European standards, represents a great opportunity for LGC and its global initiatives.  We look forward to expanding Little Green Pharma‘s production capacity and help growing its reach throughout the globe.”

Terms of the transaction:

Subject to TSXV approval, LGC Capital will pay to the vendor of the shares, AUS$5.5M. Closing of this transaction is expected to be within 95 days of signing the agreement.

Statutory information: For the financial year end 30 June 2018, Little Green Pharma generated Revenue of AUS$8,337 and had a net loss for the period of AUS$3,757,810.  This was first year that the company was operational as a legal cannabis business.

About LGC Capital Ltd (www.lgc-capital.com)

LGC Capital is a leading cannabis investment firm with a focus on the legal global cannabis market. Through its growing portfolio of investment companies, LGC is building a transversal integrated organization of interconnected legal cannabis companies with cultivation, processing and distribution in Australia, Jamaica, Switzerland, Italy, and Canada serving domestic and export markets. LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: LG) and the US OTC-QB exchange (OTCQB: LGGCF).

Through its partners and assuming pending transactions under review by the TSXV are approved, LGC has interests in Jamaica, Switzerland, Italy, Canada and Australia.

LGC partners currently sell cannabis products in over 1,000 points of sale across Switzerland and Italy under the ONE Premium Cannabis and EasyJoint brands as well as medical cannabis oils in Australia under the Little Green Pharma brand. LGC’s partners’ branded products are available in a variety of formats including medicines, cosmetics, dry cannabis flower, tinctures, oils and seeds.

About Little Green Pharma, Perth Australia (https://lgpharma.com.au):

LGP was the first Australian company to locally-grow and produce medicinal cannabis products for sale to Australian patients. The medicines are cultivated, without pesticides, in a hydroponic facility in Western Australia’s southwest region and processed in a manufacturing facility near Perth. LGP products have been subject to extensive assessment and testing based on the Australian TGA regulation, before being distributed under Australia’s tightly controlled medical prescription system. Under the Australian system, medicinal cannabis products must be prescribed by medical practitioners and sold by registered pharmacists. Medicinal cannabis has been prescribed in Australia for over 51 conditions.

For further information please contact:

President, John McMullen, +1-416-803-0698, john@lgc-capital.com
Chief Financial Officer, Mark Shinners, mark@lgc-capital.com

Caution Regarding Press Releases

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice Regarding Forward Looking Statements
This press release may contain forward-looking statements with respect to LGC and their respective operations, strategy, investments, financial performance and condition. These statements can generally be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of LGC and LGP could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under “Risk Factors and Risk Management” in LGC’s Management’s Discussion and Analysis for the three months ended December 31, 2018, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and neither LGC nor LGP has any obligation to update such statements, except to the extent required by applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

LGC Capital announces that it has increased its ownership to 40.4% of Little Green Pharma in Australia

MONTRÉAL, May 22, 2019 (GLOBE NEWSWIRE) — LGC Capital Ltd. (TSXV: LG) (OTCQB: LGGCF) (“LGC” or the “Corporation”) announces that after much negotiation, it has successfully acquired, from a non-executive founder, additional shares in Australia’s licensed medical cannabis producer Little Green Pharma (LGP) bringing its ownership from 14.1% up to 40.4%.

LGP was the first, and is currently the only, domestic cannabis company in Australia producing a locally grown medicinal cannabis medicine for patients.  LGC believes the opportunity to increase its ownership in LGP creates significant value for its shareholders and enables the Corporation to further take part in the rapidly expanding Australian medical cannabis market.

Little Green Pharma has had over 400 patients approved in Australia, with new patients increasing exponentially month-over-month. The Australian industry represents one of the fastest growing international medical cannabis markets globally, with approximately 6,400 SAS B forms approved to the end of April 2019 of which 1,110 occurred in April alone.  Prohibition Partners estimates that the Australian medical cannabis market could be worth US$2 billion by 2028 and US$8.7 billion if adult use was to become legal.

Little Green Pharma produces its products in compliance with Australia’s strict Therapeutic Goods Order 93 Standard for Medicinal Cannabis and is one of only a handful of companies with an EU GMP recognised medical cannabis facility.

Expansion plans for LGP‘s cultivation facility have been submitted to Australia’s Office of Drug Control to increase production capacity in order to supply the Company’s growing demand for its products in Australia as well as to export product via its new distribution agreements in Germany, the United Kingdom, Canada and New Zealand.

Mazen Haddad, CEO of LGC Capital, stated; “Little Green Pharma was one of our first investments and as its business and opportunities expanded, and the opportunity to increase our shareholding to over 40% is a significant move for the Company. To be the first in Australia to grow and produce a full line of Medical THC Cannabis products, in accordance with both Australian and European standards, represents a great opportunity for LGC and its global initiatives.  We look forward to expanding Little Green Pharma‘s production capacity and help growing its reach throughout the globe.”

Terms of the transaction:

Subject to TSXV approval, LGC Capital will pay to the vendor of the shares, AUS$5.5M. Closing of this transaction is expected to be within 95 days of signing the agreement.

Statutory information: For the financial year end 30 June 2018, Little Green Pharma generated Revenue of AUS$8,337 and had a net loss for the period of AUS$3,757,810.  This was first year that the company was operational as a legal cannabis business.

About LGC Capital Ltd (www.lgc-capital.com)

LGC Capital is a leading cannabis investment firm with a focus on the legal global cannabis market. Through its growing portfolio of investment companies, LGC is building a transversal integrated organization of interconnected legal cannabis companies with cultivation, processing and distribution in Australia, Jamaica, Switzerland, Italy, and Canada serving domestic and export markets. LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: LG) and the US OTC-QB exchange (OTCQB: LGGCF).

Through its partners and assuming pending transactions under review by the TSXV are approved, LGC has interests in Jamaica, Switzerland, Italy, Canada and Australia.

LGC partners currently sell cannabis products in over 1,000 points of sale across Switzerland and Italy under the ONE Premium Cannabis and EasyJoint brands as well as medical cannabis oils in Australia under the Little Green Pharma brand. LGC’s partners’ branded products are available in a variety of formats including medicines, cosmetics, dry cannabis flower, tinctures, oils and seeds.

About Little Green Pharma, Perth Australia (https://lgpharma.com.au):

LGP was the first Australian company to locally-grow and produce medicinal cannabis products for sale to Australian patients. The medicines are cultivated, without pesticides, in a hydroponic facility in Western Australia’s southwest region and processed in a manufacturing facility near Perth. LGP products have been subject to extensive assessment and testing based on the Australian TGA regulation, before being distributed under Australia’s tightly controlled medical prescription system. Under the Australian system, medicinal cannabis products must be prescribed by medical practitioners and sold by registered pharmacists. Medicinal cannabis has been prescribed in Australia for over 51 conditions.

For further information please contact:

President, John McMullen, +1-416-803-0698, john@lgc-capital.com
Chief Financial Officer, Mark Shinners, mark@lgc-capital.com

Caution Regarding Press Releases

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Notice Regarding Forward Looking Statements
This press release may contain forward-looking statements with respect to LGC and their respective operations, strategy, investments, financial performance and condition. These statements can generally be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of LGC and LGP could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under “Risk Factors and Risk Management” in LGC’s Management’s Discussion and Analysis for the three months ended December 31, 2018, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and neither LGC nor LGP has any obligation to update such statements, except to the extent required by applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Virtusa recognized as a Visionary in the Magic Quadrant for CRM and Customer Experience Implementation Services, Worldwide

SOUTHBOROUGH, Mass., May 22, 2019 (GLOBE NEWSWIRE) — Virtusa Corporation (NASDAQ GS:VRTU), a global provider of digital strategy, digital engineering, and IT outsourcing services that accelerates business outcomes for its clients, today announced that Gartner, Inc. has positioned Virtusa in the Visionaries Quadrant of the 2019 Magic Quadrant for CRM and Customer Experience (CX) Implementation Services, Worldwide. The report evaluated Virtusa along with 17 other companies in CRM and Customer Experience Implementation Services.  Virtusa was one of only three companies to be categorized as a Visionary.

According to Gartner, “The CX and CRM implementation service market is completing the shift from the implementation of core CRM technology to complex initiatives that not only transform the front office but integrate across the full enterprise’s operations. Customers now demand that organizations provide them with a continuous experience, preserving continuity of user experience across traditional boundaries of devices, time and space. To fulfill their journeys, customers want to seamlessly interact with enterprises across multiple devices and channels (both digital and physical) in a multistep sequence that can last over an extended period of time.”

“Virtusa provides clients with differentiated experiences, making us well situated to capitalize on the CRM and Customer Expereince Services market opportunity,” said Madhavan Satagopan, EVP, Virtusa.  “We believe this recognition validates Virtusa’s unique approach and framework to improve client experiences by combining our strong domain knowledge and deep engineering heritage to deliver innovative CRM and CX digital solutions to our clients.”

Harnessing deep industry knowledge, a consulting led approach, and strong digital engineering competencies, Virtusa helps its clients re-imagine and transform their IT environments and platforms to meet the needs of today’s digital economy focused on speed, convenience and engagement. Virtusa’s Content and Customer Experience (CCX) group has partnered with leading technology vendors to help global enterprises design, develop and deploy customer experience solutions that deliver immersive digital experiences, expand addressable markets and drive competitive advantage.

To learn more about Virtusa’s CRM and Customer Experience Implementation Services, please visit  http://www.virtusadigital.com/

For more information and to access the report (subscription required):

https://www.gartner.com/doc/3843472/magic-quadrant-crm-customer-experience

Gartner, Magic Quadrant for CRM and Customer Experience Implementation Services, Worldwide, Patrick Sullivan, Ed Thompson, 7 February 2019

Gartner Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a purpose.

About Virtusa Corporation
Virtusa Corporation (NASDAQ GS: VRTU) is a global provider of digital business transformation, digital engineering and information technology (IT) outsourcing services. Using a combination of digital strategy, business implementation, and IT platform modernization services, Virtusa helps clients drive profitable growth and lead market disruption through digital first client experiences. Founded in 1996 and headquartered in Southborough, Mass., Virtusa serves Global 2000 companies in the banking, financial services, insurance, healthcare, telecommunications, media, entertainment, travel, manufacturing and technology industries. For more information, visit: www.virtusa.com.

Virtusa, Accelerating Business Outcomes, BPM Test Drive and Productization are registered trademarks of Virtusa Corporation.  All other company and brand names may be trademarks or service marks of their respective holders.

Contact:

Kirsten Paragona
Virtusa
kparagona@virtusa.com
978-434-7319

Ron Favali
Conversion Marketing
ron@conversionam.com
727-512-4490